Hungary Pharmaceuticals & Healthcare Q1 2020

Hungary Pharmaceuticals & Healthcare Q1 2020

Key View:

We maintain a muted long-term outlook for the Hungarian pharmaceutical due to a range of factors, principally driven bya lack of funding within the healthcare system. The government spends significantly less on the health system than the EU average,both in absolute terms and as a share of GDP. Although it remains one of the larger and more-developed markets in the Central andEastern Europe region, growth opportunities will remain considerably below its regional peers. Nonetheless, innovative medicinesales will be supported by a rising chronic disease burden driven by Hungary’s ageing, albeit declining, population.


Key View
SWOT
Industry Forecast
Pharmaceutical Market Forecast
Healthcare Market Forecast
Prescription Drug Market Forecast
Patented Drug Market Forecast
Generic Drug Market Forecast
OTC Medicine Market Forecast
Pharmaceutical Trade Forecast
Industry Risk/Reward Index
Central & Eastern Europe Innovative Pharmaceuticals Risk/Reward Index
Hungary Innovative Pharmaceuticals Risk/Reward Index
Regulatory Development
Regulatory Review
Market Overview
Competitive Landscape
Company Profile
Egis Pharmaceuticals (Servier)
Gedeon Richter
Hungary Demographic Outlook
Pharmaceuticals & Healthcare Glossary
Pharmaceuticals & Healthcare Methodology

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook